In addition, prostaglandin E2, whose biosynthesis is inhibited by cyclooxygenase (COX)-blocking non-steroidal anti-inflammatory drugs (NSAIDs), has been reported to induce VEGF-C expression and lymphangiogenesis in the setting of lung cancer (73). Here, VEGFC is linked to lung carcinoma.